Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease
Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…Increasing placebo response in Parkinson’s disease through apomorphine pre-conditioning
Objective: To see whether a placebo response requires pharmacological pre-conditioning with apomorphine. Background: Placebos have been found to affect the patient's brain in a number…The neurosteroid dehydroepiandrosterone sulfate (DHEAS) reverses the dopaminergic deficiencies in mild hepatic encephalopathy: A possible therapeutic issue for the management of parkinsonism in cirrhotic patients
Objective: In the present study, we describe the changes of the dopaminergic system occurring in the cirrhotic rats and concomitantly we investigated the effect of…Role of dopamine and GABA during subthalamic and pallidal deep brain stimulation: Evidence of dopamine release during subthalamic Deep Brain Stimulation
Objective: We recorded the single-unit activity of striatal cholinergic interneurons of healthy monkeys during high-frequency stimulation (HFS) of the subthalamic nucleus (STN) and globus pallidus…Comparison of DAT scan, cardiac MIBG scintigraphy, and cerebrospinal fluid 5HIAA levels in Parkinsonian syndrome
Objective: To assess the associations of presynaptic dopamine transporter (DAT scan), cardiac 123I-meta-iodobenzylguanidine (MIBG) scintigraphy, and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5HIAA)…AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons
Objective: To characterize the effect of AMP-activated protein kinase (AMPK) on ATP-sensitive K+ (K-ATP) channels on substantia nigra compacta (SNC) dopamine neurons in slices of…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…The efficacy of quantitative 99mTc-TRODAT-1 SPECT in diagnosis of aged patients with Parkinson’s disease
Objective: We aim to establish the normal reference with quantitative 99mTc-Trodat-1 (TRODAT) SPECT and verify the diagnostic performance in aged Parkinson's disease (PD) patients. Background:…Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study
Objective: The aim of the present study was to investigated using microdialysis methodology the impact of 1MeTIQ on the disturbances of in vivo dopamine release…
- « Previous Page
- 1
- …
- 25
- 26
- 27